Results 261 to 270 of about 38,769 (305)

Preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate. [PDF]

Eur Heart J Cardiovasc Pharmacother
Karakasis P, Antoniadis AP, Fragakis N.
europepmc   +1 more source

SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications. [PDF]

J Clin Med
Kamran N, Mohammad M.
europepmc   +1 more source

GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.

JAMA Netw Open
Choi T, Al-Aly Z, Xie Y.
europepmc   +1 more source

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases

Antioxidants, 2021
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering agents. Apart from their glucose-lowering effects, large clinical trials assessing certain SGLT2 inhibitors have revealed cardiac and renal protective effects in ...
Kai-Fan Tsai, , Terry Ting-Yu Chiou
exaly   +2 more sources

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

International Journal of Molecular Sciences, 2017
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN.
Daiji Kawanami, Keiichiro Matoba, Yusuke Takeda   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

SGLT2 inhibitors

Biochemical Pharmacology, 2016
Diabetes mellitus is a serious health issue and an economic burden, rising in epidemic proportions over the last few decades worldwide. Although several treatment options are available, only half of the global diabetic population achieves the recommended or individualized glycemic targets.
I, Dardi, T, Kouvatsos, S A, Jabbour
openaire   +2 more sources

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function [PDF]

Annual Review of Physiology, 2021
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients with or without type 2 diabetes and preserved or reduced kidney function from failing.
Volker Vallon, Subodh Verma
exaly   +2 more sources

SGLT2 inhibitors

Current Opinion in Cardiology, 2018
To address common concerns regarding sodium-glucose cotransporter 2 (SGLT2) inhibitor use for patients with type 2 diabetes mellitus (T2DM) in cardiovascular practice.SGLT2 inhibitors provide glycemic control and improve cardiovascular and renal endpoints in T2DM.
Erika, Opingari, Arun C R, Partridge, Subodh, Verma, Harpreet S, Bajaj   +3 more
openaire   +2 more sources

Cardiovascular benefit of SGLT2 inhibitors

Critical Reviews in Clinical Laboratory Sciences, 2021
Patients with type 2 diabetes mellitus (T2D) are at increased risk of cardiovascular (CV) disease. Sodium glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, are a class of medications used to treat T2D by preventing the reabsorption of glucose filtered through the kidney and thereby facilitating glucose excretion in the urine.
Reza, Mohebi, James L, Januzzi
openaire   +2 more sources

SGLT2 inhibitors and autophagy in diabetes

Cell Biochemistry and Function, 2023
AbstractAutophagy is a physiological event in mammalian cells to promote cell survival and efficiency in tissues, but it may turn to be a pathological process in disease conditions such as in diabetes. Chronic hyperglycemia induces aberrant autophagy and promotes cellular death as a main underlying cause of diabetes‐related complications.
Habib Yaribeygi, Mina Maleki, Stephen L. Atkin, Tannaz Jamialahmadi, Amirhossein Sahebkar   +4 more
openaire   +2 more sources